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Abstract
Purpose: Kinin B1 receptor (B1R) is upregulated in retina of Streptozotocin (STZ)-diabetic rats and contributes to vasodilation
of retinal microvessels and breakdown of the blood-retinal barrier. Systemic treatment with B1R antagonists reversed the
increased retinal plasma extravasation in STZ rats. The present study aims at determining whether ocular application of a
water soluble B1R antagonist could reverse diabetes-induced retinal inflammation and oxidative stress.
Methods: Wistar rats were made diabetic with STZ (65 mg/kg, i.p.) and 7 days later, they received one eye drop application
of LF22-0542 (1% in saline) twice a day for a 7 day-period. The impact was determined on retinal vascular permeability
(Evans blue exudation), leukostasis (leukocyte infiltration using Fluorescein-isothiocyanate (FITC)-coupled Concanavalin A
lectin), retinal mRNA levels (by qRT-PCR) of inflammatory (B1R, iNOS, COX-2, ICAM-1, VEGF-A, VEGF receptor type 2, IL-1b
and HIF-1a) and anti-inflammatory (B2R, eNOS) markers and retinal level of superoxide anion (dihydroethidium staining).
Results: Retinal plasma extravasation, leukostasis and mRNA levels of B1R, iNOS, COX-2, VEGF receptor type 2, IL-1b and HIF-
1a were significantly increased in diabetic retinae compared to control rats. All these abnormalities were reversed to control
values in diabetic rats treated with LF22-0542. B1R antagonist also significantly inhibited the increased production of
superoxide anion in diabetic retinae.
Conclusion: B1R displays a pathological role in the early stage of diabetes by increasing oxidative stress and pro-
inflammatory mediators involved in retinal vascular alterations. Hence, topical application of kinin B1R antagonist appears a
highly promising novel approach for the treatment of diabetic retinopathy.
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Introduction
Recent findings suggest a role for the kallikrein-kinin system in
the development of diabetic retinopathy [1,2,3]. Kinins are
important inflammatory mediators involved in tissue edema,
leukocytes infiltration, vasodilation and regulation of local blood
flow [4]. These peptides are produced at the site of inflammation
and exert their effects through the activation of two G-protein-
coupled receptors named B1 (B1R) and B2 (B2R) [5,6]. B2Ri s
constitutively expressed and mediates mainly the acute effects of
kinins due to its rapid desensitization. In contrast, B1R is expressed
at very low levels in physiological conditions. This inducible
receptor is upregulated in response to tissue injury, by pro-
inflammatory cytokines or by the oxidative stress associated to
hyperglycemia. The B1R is involved in the chronic phase of the
inflammatory response which is compatible with its low desensi-
tization mechanism [7,8,9]. Bradykinin (BK) and kallidin (KD)
mediate the action of B2R while their kininase I metabolites des-
Arg
9-BK and des-Arg
10-KD are the preferential agonists for B1R
[7,8]. The activation of these receptors induces the release of nitric
oxide (NO), prostaglandins and pro-inflammatory cytokines
[4,10,11].
Most components of the kallikrein-kinin system have been
identified in the human, rabbit and rat retina [12,13,14,15].
Particularly, B1R was found overexpressed in the retina of
Streptozotocin (STZ)-diabetic rats through a mechanism involving
oxidative stress [16,17]. In STZ-diabetic rats, B1R mediates
vasodilation of ex vivo retinal microvessels [16] and contributes to
the breakdown of the blood-retinal barrier in vivo [17]. Collec-
tively, these results suggest a pathological role for B1R in the
development of retinal damage in diabetes and the progression of
diabetic retinopathy.
Diabetic retinopathy is characterized by vascular alterations
including retinal blood flow changes, endothelial cells dysfunction,
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larisation [18]. Oxidative stress and inflammatory processes are
thought to contribute largely to the development of the disease
[19,20,21]. Hyperglycemia induces the production of reactive
oxygen species (ROS) and the expression of many pro-inflamma-
tory factors in the diabetic retina including inducible nitric oxide
synthase (iNOS), interleukin-1b (IL-1b), cyclooxygenase-2 (COX-
2) and vascular endothelial growth factor (VEGF) [20]. Vasodi-
lation, increased vascular permeability and adhesion of inflam-
matory cells to the vascular wall are also part of the inflammatory
response occurring in the retina during diabetes [22,23,24].
The present study aims at determining whether topical ocular
application of LF22-0542, a non-peptide water soluble B1R
antagonist, could reverse diabetes-induced retinal inflammation
and oxidative stress. Our data show that the enhanced retinal
vascular permeability, leukostasis, the enhanced expression of
several inflammatory mediators and higher production of
superoxide anion levels were significantly decreased in the retina
of STZ-diabetic rats treated with LF22-0542. This provides the
first demonstration that ocular application of a kinin B1R
antagonist could be an effective strategy in the treatment of
diabetic retinopathy.
Materials and Methods
STZ-diabetic rats
All experimental methods and animal care procedures were
approved by the animal care committee of the Universite ´d e
Montre ´al (protocol 09-030), in accordance with the Canadian
Council on Animal Care. Male Wistar rats weighting 200–250 g
were purchased from Charles River (St-Constant, QC, Canada)
and housed two per cage in a room under controlled temperature
(23uC), humidity (50%) and lighting (12-hour light/dark cycle)
with food and water provided ad libitum. Rats were rendered
diabetic by a single i.p. injection of Streptozotocin (STZ, Zanosar
65 mg/kg, Sigma-Aldrich, Oakville, ON, Canada). Age-matched
control rats were injected with vehicle (sterile saline 0.9%, pH.
7.4). Glucose concentrations were measured in blood samples
obtained from the tail vein with a commercial blood glucose
analyzer (Accusoft; Roche Diagnostics, Laval, QC, Canada). Only
STZ-treated rats with blood glucose concentration higher than
20 mmol/L were considered as diabetic and included in the study.
Glycemia and body weight were recorded twice a week and on the
day of the experiment.
Topical ocular treatment with B1R antagonist LF22-0542
Seven days after diabetes induction, rats were treated twice a
day (8:30 AM and 5:30 PM) with one eye drop application of the
water soluble B1R antagonist LF22-0542 (1% in saline) for a 7-day
period. LF22-0542 (N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-
methyl]-2-[2-[[(4-methoxy-2,6 dimethylphenyl)sulfonyl]methyla-
mino]ethoxy]-N-methyl-acetamide, fumarate) is a competitive
non-peptide B1R antagonist which was synthesized and provided
by Fovea Pharmaceuticals SA, Paris, France. The chemical
structure of LF22-0542 is presented in Figure 1. LF22-0542
showed high affinity for human and mouse B1R with virtually no
affinity for the human B2R; a selectivity index of at least 4000
times was obtained when LF22-0542 was profiled throughout
binding or cell biology assays on 64 other G-protein-coupled
receptor, 10 ion channels, and seven enzymes [25]. LF22-0542
blocked pain behavior in various inflammatory and neuropathic
pain models in rats and mice and was found inactive in B1R
knockout mice models of inflammatory pain [25,26,27]. Fresh
solution was prepared daily by dissolving the compound in saline
0.9% and sterilizing the solution by filtration (0.20 mm mesh). For
ocular instillation, rats were firmly maintained and a drop of
solution (10 ml) was instilled on the surface of the eye using a
micropipette. Animals were maintained 10 s in order to make sure
that the drop effectively remained on the surface of the eye. Every
day, the rats were visually inspected to detect the presence of
ocular irritation such as redness, porphyrin secretion or corneal
opacity. All end points were determined on the last day of
treatment.
Measurement of retinal vascular permeability
Retinal vascular permeability was assessed using Evans blue dye
extravasation technique as previously described [17]. Rats were
anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and a
catheter (Micro-Renathane, I.D. 0.0400, O.D. 0.0200, Braintree
Scientific, Braintree, MA, USA) was inserted into the right femoral
vein. Evans blue dye (45 mg/ml in saline) (Sigma-Aldrich,
Oakville, ON, Canada) was injected i.v. over 10 s. The dye was
allowed to circulate for 2 h and then saline (25 ml) was infused
through the left ventricle, to wash out intravascular dye. Following
enucleation, retinae were dissected out and immediately weighed.
Evans blue dye was then extracted by incubating each retina in
1 ml formamide (Sigma-Aldrich, Oakville, ON, Canada) for 18 h
at 70–75uC. The fluorescence of Evans blue was measured using a
spectrofluorometer (Spex 1681 0.22 m, Horiba JobinYvon Inc,
Edison, NJ, USA) at 620 nm (excitation) and 680 nm (emission).
Measurement of retinal leukostasis
Rats were anesthetized with isoflurane, the chest cavity was
opened and a 16G cannula was inserted into the left heart
ventricle. Rats were perfused with phosphate buffer saline (PBS)
over 1 min (35 ml/min) to eliminate erythrocytes and non-
adherent leukocytes. Fluorescein-isothiocyanate(FITC)-coupled
Concanavalin A lectin (20 mg/ml in PBS, 5 mg/kg; Vector Labs,
Burlington, ON, Canada) was infused at 30 ml/min to label
adherent leukocytes and vascular endothelial cells. Rats were
perfused with 4% paraformaldehyde over 4 min followed by 1%
Albumin in PBS over 1 min and PBS over 2 min (35 ml/min).
Retinae were dissected out, flat mounted on a glass slide and
imaged using a fluorescence microscope (Leica microsystems Co.,
Germany). The total number of leukocytes in each retina was
determined under microscope examination at 406.
Measurement of retinal inflammatory mediators by
quantitative RT-PCR
Rats were anaesthetized with sodium pentobarbital (60 mg/kg,
i.p.) and the eyes were dissected out. The retinae were isolated and
put in RNAlater stabilization reagent (QIAGEN, Valencia, CA,
USA). Total RNA was extracted from retinae using a commercial
Figure 1. Chemical structure of LF22-0542.
doi:10.1371/journal.pone.0033864.g001
Kinin B1R in Diabetes-Induced Retinal Inflammation
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33864kit (QIAGEN, Valencia, CA, USA). First-strand cDNA synthe-
sized from 400 ng total RNA with random hexamer primers was
used as template for each reaction with the QuantiTect Rev
Transcription Kit (QIAGEN). SYBR Green-based real-time
quantitative PCR using Mx3000p device for signal detection
(Stratagene, La Jolla, CA, USA) was performed as previously
described [17]. PCR was performed in SYBR Green Master mix
(QIAGEN) with 300 nM of each primer. The primer pairs
designed by Vector NTI software are shown in Table 1. For
standardization and quantification, rat 18S was amplified
simultaneously. PCR conditions were as follows: 95uC for
15 min, followed by 46 cycles at 94uC for 15 s, 60uC for 30 s
and 72uC for 30 s. The cycle threshold (Ct) value represents the
cycle number at which a fluorescent signal rises statistically above
background. The relative quantification of gene expression was
analyzed by the 2
2DDCt method [28].
Measurement of superoxide anion production in the
retina
Rats were sacrificed with CO2 inhalation and the eyes were
dissected out, frozen in isopentane (255uC), cut into 20-mm thick
sections and placed on glass slides. Superoxide anion (O2
N2)
production was measured in retina using the oxidative fluorescent
dye dihydroethidium (DHE) as described earlier [29]. Cells are
permeable to hydroethidine and, in the presence of O2
N2,i ti s
oxidized to fluorescent ethidium bromide (EtBr) which is trapped
by intercalation with DNA. EtBr is excited at 518 nm with an
emission spectrum of 605 nm. Dihydroethidium (2 mM) (Sigma-
Aldrich, Oakville, ON, Canada) was applied to 20-mm thick eye
sections and the slides were then incubated in a light-protected
humidified chamber at 37uC for 30 min. Nuclei of retinal cells
were stained with TO-PRO-3 (Molecular Probes, Eugene, Ore,
USA). Images were obtained with a Leica TCS SP confocal
microscope equipped with an argon laser (Leica microsystems Co.,
Germany). Tissues from each experimental group were processed
and imaged in parallel. Laser settings were identical for acquisition
of images from all sections. Leica LCS Lite software was used to
quantify the mean pixel energy of DHE and TO-PRO-3 in the
retinal ganglion cells (RGC) layer, the inner nuclear layer (INL)
and the outer nuclear layer (ONL). Data were expressed as the
mean pixel energy ratio between DHE and TO-PRO-3 from an
average of 10 nuclei in the RGC layer or 20 nuclei in the INL and
ONL for each retinal image quantified in 3 rats.
Statistical analysis
Data were expressed as mean 6 s.e.m. and n represents the
number of rats used in each experiment. Multiple comparisons
between groups were performed using the non-parametric Mann-
Whitney test for retinal leukostasis. One-way ANOVA and the
Bonferroni post-hoc test were used for Table 2 data, vascular
permeability, expression of inflammatory mediators and superox-
ide anion measurement. Only probability values (P) less than 0.05
were considered to be statistically significant.
Results
Physiological parameters
As shown in Table 2, blood glucose concentration was
significantly increased in STZ-diabetic rats at the time of sacrifice
when compared to age-matched control rats (P,0.001). One-week
Table 1. Primers list.
Sequence Position Gen Bank
B1R Forward 59 GCA GCG CTT AAC CAT AGC GGA AAT 39 367 - 390 NM_030851
Reverse 59 CCA GTT GAA ACG GTT CCC GAT GTT 39 454 - 431
B2R Forward 59 AGG TGC TGA GGA ACA ACG AGA TGA 39 882 - 905 NM_173100
Reverse 59 TCC AGG AAG GTG CTG ATC TGG AAA 39 990 - 967
iNOS Forward 59 TGA TCT TGT GCT GGA GGT GAC CAT 39 1150 - 1173 NM_012611
Reverse 59 TGT AGC GCT GTG TGT CAC AGA AGT 39 1349 - 1326
eNOS Forward 59 TAT TTG ATG CTC GGG ACT GCA GGA 39 587 - 610 NM_021838
Reverse 59 ACG AAG ATT GCC TCG GTT TGT TGC 39 678 - 655
COX-2 Forward 59 GCA TTC TTT GCC CAG CAC TTC ACT 39 677 - 700 U03389
Reverse 59 TTT AAG TCC ACT CCA TGG CCC AGT 39 744 - 751
ICAM-1 Forward 59 TGC AGG TGA ACT GCT CTT CCT CTT 39 161 - 184 NM_012967
Reverse 59 AGC TTC CAG TTG TGT CCA CTC GAT 39 263 - 240
VEGF-A Forward 59 TCA CCA AAG CCA GCA CAT AGG AGA 39 1219 - 1242 BC168708
Reverse 59 TTA CAC GTC TGC GGA TCT TGG ACA 39 1371 - 1348
VEGF-R2 Forward 59 AGT GGC TAA GGG CAT GGA GTT CTT 39 3269 - 3292 U93306
Reverse 59 GGG CCA AGC CAA AGT CAC AGA TTT 39 3387 - 3364
IL-1b Forward 59 TGT CAC TCA TTG TGG CTG TGG AGA 39 247 - 270 NM_031512
Reverse 59 TGG GAA CAT CAC ACA CTA GCA GGT 39 411 - 388
HIF-1a Forward 59 TAG ACT TGG AAA TGC TGG CTC CCT 39 1693 - 1716 NM_024359
Reverse 59 TGG CAGTGA CAG TGA TGG TAG GTT 39 1863 - 1840
18S Forward 59 TCA ACT TTC GAT GGT AGT CGC CGT 39 363 - 385 X01117
Reverse 59 TCC TTG GAT GTG GTA GCC GTT TCT 39 470 - 447
doi:10.1371/journal.pone.0033864.t001
Kinin B1R in Diabetes-Induced Retinal Inflammation
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33864eye drops application of LF22-0542 had no effect on glycemia in
both control and STZ-diabetic rats (P.0.05). Body weight was
significantly reduced in STZ-diabetic rats treated or not with
LF22-0542 compared to controls (P,0.001). Treatment of
diabetic rats with LF22-0542 had no effect on body weight when
compared to diabetic rats treated with the vehicle (P.0.05).
Control and STZ-diabetic rats that received eye drops of LF22-
0542 did not show symptoms of ocular irritation (redness or
corneal opacity) or the presence of porphyrin secretion around the
eyes during the whole period of treatment.
Effect of LF22-0542 on retinal vascular permeability
Evans Blue extravasation (mg/g of fresh tissue) was significantly
increased by 31% in STZ-diabetic rats compared to control rats
(P,0.05). Topical ocular administration of LF22-0542 reversed
retinal vascular hyperpermeability to control values in STZ-
diabetic rats (P,0.05) (Figure 2).
Effect of LF22-0542 on retinal leukostasis
Retinal adherent leukocytes were labelled with FITC-Conca-
navalin A lectin (Figure 3A). Total number of adherent leukocytes
in the retinal wall was significantly increased in STZ-diabetic rats
compared to control rats (P,0.05) (Figure 3B). One-week eye
drops administration of LF22-0542 to diabetic rats significantly
decreased retinal leukostasis (P,0.05). B1R antagonist treatment
had no significant effect on leukocytes number in control retina
(P.0.05).
Effect of LF22-0542 on the expression of inflammatory
mediators
All inflammatory mediators were expressed at very low levels in
the retina of control rats (Figure 4). In STZ-diabetic rats (n=7),
retinal mRNA levels of B1R, iNOS, IL-1b, COX-2, VEGF-R2
and HIF-1a were significantly increased (4 to 16-fold) compared to
control rats (n=7, P,0.05). These increases were restored to
control values in rats treated with LF22-0542 (n=7). The increase
mRNA levels of B2R, ICAM-1, eNOS and VEGF-A did not reach
statistical significance in STZ-diabetic retinae, yet LF22-0542
treatment abolished to control values this trend.
Effect of LF22-0542 on oxidative stress
Production of superoxide anion (O2
N2) in the retina measured
with the oxidative fluorescent dye dihydroethidine is shown in
Figure 5. DHE staining of STZ-diabetic retinal sections displayed
a higher intensity of fluorescence than controls (Figure 5A).
Quantification of the O2
N2 retinal levels (mean pixel energy ratio
of DHE staining versus TO-PRO-3) showed a significant increase
in the retinal ganglion cells layer (RGC) (P,0.01), the inner
nuclear layer (INL) (P,0.01) and the outer nuclear layer (ONL)
(P,0.01) of STZ-diabetic rats compared to control rats (Figure 5B).
Importantly, one-week topical administration of LF22-0542 to
STZ-diabetic rats markedly reduced O2
N2 levels in the 3 retinal
nuclear layers (P,0.05). Administration of LF22-0542 had no
significant effect on basal production of O2
N2 in the retina of
control animals (P.0.05).
Discussion
This study provides the first demonstration that prolonged
ocular application of a water soluble non-peptide kinin B1R
antagonist is an effective and non-toxic approach to inhibit
diabetes-induced retinal inflammation and oxidative stress. The
results clearly show that the B1R antagonist reversed the increased
vascular permeability, leukostasis, the enhanced expression of
several inflammatory mediators and the higher production of
reactive oxygen species.
Retinal vascular permeability
Breakdown of the blood-retinal barrier appears early in the
progression of diabetic retinopathy and often leads to the
development of macular edema which is a major cause of visual
impairment in diabetic patients [30,31]. Retinal vascular perme-
ability has been largely studied in experimental models of diabetes
and evidence was provided that breakdown of the blood-retinal
barrier occurs as early as one week following diabetes induction in
rats [24,32]. The present study shows that 7-day eye drops
application of the B1R antagonist LF22-0542 completely reversed
increased retinal vascular permeability in 2-week STZ-diabetic
rats. This is consistent with the inhibition of retinal plasma
extravasation following a 7-day i.v. treatment with the peptide
B1R antagonist R-715 in STZ-diabetic rats [17]. Likewise, s.c. or
i.v. injection of the peptide B1R antagonist R-954 reversed the
enhanced vascular permeability in the retina and other target
tissues in mice and rats treated with STZ 1 and 4 weeks earlier
[33,34,35]. Our results are also consistent with a previous study
that showed a decrease in retinal vascular permeability following
treatment with a selective plasma kallikrein inhibitor in STZ-
diabetic rats [36].
The alleviation of enhanced vascular permeability by B1R
antagonism could be explained by the concomitant reduction in
gene expression of iNOS, COX-2 and VEGF-R2 in rats treated
with LF22-0542. Nitric oxide pathway, prostaglandins and VEGF
Table 2. Effect of diabetes and LF22-0542 on glycemia and
body weight.
Glycemia (mmol/L) Body weight (g)
Control+Vehicle (n=7) 5.5 6 0.2 356 6 6
Control+LF22-0542 (n=6) 5.1 6 0.2 355 6 5
STZ+Vehicle (n=5 ) 26.8 6 2.9*** 295 6 9***
STZ+LF22-0542 (n=7) 27.7 6 2.9*** 274 6 5***
Values are mean 6 s.e.m.
***P,0.001, significantly different from control group.
doi:10.1371/journal.pone.0033864.t002
Figure 2. Effect of LF22-0542 on retinal vascular permeability
in STZ-diabetic rats. Data are mean 6 s.e.m. of values obtained from
9 to 11 rats. Statistical comparison with control (*) or STZ (+) rats is
indicated by *
+P,0.05.
doi:10.1371/journal.pone.0033864.g002
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through a mechanism involving the upregulation of intercellular
adhesion molecules (ICAM-1) and the downregulation of tight
junctions proteins in the retinal vasculature [37,38,39]. Moreover,
B1R is known to be expressed on retinal vessels and could
therefore directly increase vascular permeability through the
release of NO and prostaglandins following its activation.
In addition to supporting a key role for kinin B1R in retinal
vascular permeability, our results demonstrate that LF22-0542
reached the rat retina when given by eye drops application. This is
the first use of a B1R antagonist as ocular treatment. LF22-0542
had a specific action at the ocular level and was not detected in the
blood circulation after prolonged ocular administration in rabbits
(unpublished data). Therefore, eye drops application provides the
advantage of avoiding systemic effects for potential clinical
treatment. Moreover, topical treatment is the less invasive route
of administration for treatment of ocular disease and would be
beneficial for the treatment of diabetic retinopathy. Current
therapies for these patients include laser induced retinal photoco-
agulation and repetitive intravitreous injections of anti-VEGF
molecules, which are very expensive and associated with
significant risks of infection, retinal lesion and pain. These
treatments help to reduce the progression of diabetic retinopathy
in advanced stages of the disease but are not curative. Topical B1R
antagonist is therefore a very promising approach for the
treatment of early pathological changes in the diabetic retina.
Leukostasis
Leukocytes adhesion to the retinal vasculature is thought to be
associated with endothelial cell death, capillary occlusion and
increased vascular permeability, which all contribute to the
progression of diabetic retinopathy [21,22]. Following their
adherence to the retinal vessels of diabetic rats, leukocytes exit
the vasculature and transmigrate to the neural retina [24,40,41].
Our data suggest that B1R antagonism is a possible therapeutic
strategy for reversing retinal leukostasis and the associated vascular
alterations in diabetes. Previously, B1R has been shown to be
involved in all 3 phases of the leukocyte recruitment process in
inflamed tissue [42,43]. B1R agonist caused leukocytes rolling,
adhesion and emigration in mouse mesenteric postcapillary
venules [44] and leukocytes migration and infiltration in the
pleural cavity [45,46].
Leukocytes bind to ICAM on the surface of endothelial cells to
adhere to the vasculature. Previous studies reported that the
increased number of adherent leukocytes in the diabetic retina is
mediated by the concomitant increase of ICAM-1 expression in
the retinal vasculature [24,47]. Importantly, our results show a
reduced level of expression of ICAM-1 in the retina of STZ-
diabetic rats treated with LF22-0542 in parallel with the decrease
of leukostasis.
Expression of B1R and B2R
Real time RT-PCR analysis revealed that B1R was significantly
upregulated in the retina of STZ-diabetic rats which is consistent
with the increased density of B1R binding sites previously reported
by autoradiography [16] and with the increased B1R protein
expression by western blot [48]. The activation of B1R is known to
induce the production of pro-inflammatory cytokines that can
directly cause the expression of B1R. The prolonged ocular
treatment with B1R antagonist inhibits both the inflammatory
response and expression of B1R. Level of B2R gene expression in
the retina of diabetic rats was slightly but not significantly
increased in the diabetic retina, yet it was reduced to control
values in diabetic rats treated with LF22-0542. Further studies are
needed to clarify the contribution of B2R in the effects mediated by
B1R blockade.
Expression of inflammatory mediators
Our results demonstrate that B1R plays a central role in retinal
inflammation by interacting with many pro-inflammatory factors
involved in vascular alterations. mRNA levels of IL-1b, COX-2
and VEGF-R2 were increased in diabetic retinas compared to
Figure 3. Effect of LF22-0542 on retinal leukostasis in STZ-diabetic rats. (A) Representative pictures of adherent leucocytes in retinal vessels
of a control rat, a control rat treated with LF22-0542, a STZ-diabetic rat and a STZ-diabetic rat treated with LF22-0542. Scale bar is 50 mm. (B) Number
of adherent leukocytes per retina. Data are mean 6 s.e.m. of values obtained from 5 to 7 rats in each group. Statistical comparison with control (*) or
STZ (+) rats is indicated by *
+P,0.05.
doi:10.1371/journal.pone.0033864.g003
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treatment. Previous studies also reported increased expression of
IL-1b and COX-2 in the retina of diabetic rats [49,50]. VEGF is
also known to play a central role in the development of diabetic
retinopathy since it is involved in neovascularisation and increased
vascular permeability [38,39,50]. Moreover, our results show that
Figure 4. Effect of LF22-0542 on the expression of retinal inflammatory mediators in STZ-diabetic rats. mRNA levels of B1R, B2R, eNOS,
iNOS, ICAM-1, IL-1b, COX-2, HIF-1a,VEGF-R2 and VEGF-A. Data are mean 6 s.e.m. of values obtained from 7–8 rats in each group. Statistical
comparison with control rats (*) is indicated by *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0033864.g004
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retina as previously shown in diabetic rodents and patients [51,52],
and this was normalized by LF22-0542. Whereas B2R-mediated
eNOS activation leads to a transient (5 min) output of NO, B1R-
mediated iNOS activation leads to a very high and prolonged
(90 min) NO production in human endothelial cells which is
consistent with the detrimental effect of iNOS on vascular function
[53]. The protective vascular function of eNOS through the
release of NO appears intact in STZ-diabetic retina at this early
stage as evidenced by the lack of alterations in eNOS expression.
This is supported by a recent study on retinal blood flow showing
that the endothelium-dependent relaxation mediated by B1R
agonist was not impaired in this model up to 6 weeks post-STZ
(Pouliot, M., He ´tu S.,Vaucher, E., Couture, R., unpublished data).
Our results also demonstrate that HIF-1a was increased in
diabetic retina and normalized with B1R antagonist. HIF-1a is a
transcription factor that accumulates in cells during hypoxia and
heterodimerizes with the constitutively expressed HIF-1b subunit,
triggering the activation of many genes such as VEGF. Retinal
HIF-1a was previously found to be activated in 2-week STZ-
diabetic rats and to directly regulate VEGF gene expression [54].
Ischemia takes place early in the diabetic retina and our results
show that B1R antagonism may be effective in reducing HIF-1a
expression and subsequent retinal ischemia.
Oxidative stress
Compelling evidence suggests that oxidative stress induced by
hyperglycemia plays an important role in the development of
vascular alterations in the retina [19,55]. Oxidative stress is
produced by multiple cell types in the retina including endothelial
cells, pericytes and glial cells [19,56,57,58]. In agreement with
previous studies conducted in diabetic mice and rats [56,59,60],
we found increased production of superoxide anion in the retina of
STZ-diabetic rats, which was reversed by LF22-0542. Since retinal
B1R overexpression was reversed by an antioxidant in STZ-
diabetic rats [17], it was concluded that the oxidative stress
associated with hyperglycemia is responsible for the induction of
B1R in the retina. Herein, data suggest that the stimulation of B1R
can perpetuate the harmful production of ROS, and therefore the
blockade of B1R should interrupt this deleterious vicious cycle,
since inflammation can induce oxidative stress and vice versa. This is
in keeping with other relevant findings. In cardiac tissue,
nitrotyrosine protein level, a marker of oxidative stress, was
reduced in B1R knockout diabetic mice [61]. In a rat model of
insulin resistance, one-week treatment with the orally active B1R
antagonist SSR240612 reversed increased levels of superoxide
anion and B1R expression in the aorta through the inhibition of
NADPH oxidase [62].
The alleviation of oxidative stress in the diabetic retina by B1R
antagonist could explain the reduction in the expression of
inflammatory mediators. It is known that oxidative stress resulting
from the production of ROS triggers the activation of the nuclear
transcription factor kappa B (NF-kB) [63]. NF-kB is a widely
expressed inducible transcription factor and an important
regulator of many genes involved in inflammatory and immune
responses including IL-1b, ICAM-1, iNOS, COX-2 and B1R
[20,64]. Therefore, by reducing oxidative stress in the retina, B1R
antagonist could indirectly inhibit NF-kB activation and thereby
inflammation, including the expression of its own receptor.
Conclusion
The findings suggest that B1R is involved in the inflammatory
cascade leading to retinal vascular damage in the early stages of
diabetes. The oxidative stress associated with hyperglycemia
induces the expression of B1R in the retina. In turn, the activation
of B1R may perpetuate the production of ROS to enhance the
expression of vascular pro-inflammatory mediators (COX-2, IL-
1b, ICAM-1, VEGF and HIF-1a). Those mediators in concert
with B1R could enhance leukostasis and vascular permeability in
the diabetic retina. These pathological events are likely to
contribute to the development of diabetic retinopathy. Hence,
the ocular application of LF22-0542, a highly potent antagonist at
human B1R, represents a promising therapeutic approach in
diabetic retinopathy.
Figure 5. Effect of LF22-0542 on retinal oxidative stress in STZ-diabetic rats. (A) Representative pictures of superoxide anion production
stained with dihydroethidine on retinal section from a control rat, a control rat treated with LF22-0542, a STZ-diabetic rat and a STZ-diabetic rat
treated with LF22-0542. Scale bar is 75 mm. (B) Fluorescence intensity of superoxide anion was quantify by the evaluation of mean pixel energy ratio
of DHE staining versus TO-PRO-3 in the retinal ganglion cells layer (RGC), the inner nuclear layer (INL) and the outer nuclear layer (ONL). Data are
mean 6 s.e.m. of values obtained from 3 rats in each group. Statistical comparison with control (*) or STZ (+) rats is indicated by **P,0.01,
+P,0.05,
+++P,0.001.
doi:10.1371/journal.pone.0033864.g005
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